Pacira BioSciences (PCRX)

• Market cap: $1.05B
• 1 day: 2.15%
• 5 days: 8.14%
• 1 month: 18.96%
• 3 months: 31.79%
• 6 months: 13.01%
• Year to date: 24.60%
• 1 year: -29.29%
• 5 years: -47.96%
• 10 years: -77.12%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Employees: 712

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

26% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 68

17% more call options, than puts

Call options by funds: $6.72M | Put options by funds: $5.74M

1.76% less ownership

Funds ownership: 113.94% [Q2] → 112.17% (-1.76%) [Q3]

15% less funds holding

Funds holding: 278 [Q2] → 236 (-42) [Q3]

44% less first-time investments, than exits

New positions opened: 49 | Existing positions closed: 88

49% less capital invested

Capital invested by funds: $1.52B [Q2] → $779M (-$738M) [Q3]

75% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 1 (-3) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 26% downside
• Avg. target: $26 14% upside
• High target: $39 71% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

RBC Capital Gregory Renza 30% 1-year accuracy 26 / 86 met price target	21% downside $18	Sector Perform Reiterated	14 Jan 2025
Needham Serge Belanger 35% 1-year accuracy 46 / 130 met price target	31% upside $30	Buy Maintained	13 Jan 2025
HC Wainwright & Co. Oren Livnat 46% 1-year accuracy 21 / 46 met price target	71% upside $39	Buy Reiterated	4 Dec 2024
Barclays Balaji Prasad 44% 1-year accuracy 20 / 45 met price target	26% downside $17	Equal-Weight Maintained	12 Nov 2024